期刊文献+

肾功能不全冠心病患者危险因素控制及药物治疗进展 被引量:5

暂未订购
导出
摘要 多项研究指出慢性肾病是引起心血管疾病的危险因素。慢性肾病与冠心病发病率和死亡率密切相关,且即使轻度肾功能受损也可影响冠心病预后。慢性肾病往往与高龄、高血压、糖尿病等冠心病危险因素伴发,也与炎症反应加剧、内皮功能异常、同型半胱氨酸血症、凝血因子激活等冠脉病变的共同机制有关。大量研究显示,去除以上因素后肾功能损害仍然是影响冠脉病变预后的独立危险因素,控制传统危险因素也是改善冠心病合并慢性肾功能损害患者预后的重要措施。本文旨在通过分析最近公布的研究结论,探讨冠心病合并肾功能损害患者的危险因素控制及药物治疗。
出处 《国际心血管病杂志》 2007年第6期398-401,共4页 International Journal of Cardiovascular Disease
基金 上海市科委重大项目(05DZ19503)
  • 相关文献

参考文献17

  • 1[1]Shlipak MG,Fried LF,Crump C,et al.Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency[J].Circulation,2003,107 (1):87-92.
  • 2[2]Berger AK,Duval S,Krumholz HM.Aspirin,beta-blocker,and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction[J].J Am Coll Cardiol,2003,42(2):201-208.
  • 3[3]Hillege HL,Gilst WH,Veldhuisen DJ,et al.Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition:the CATS randomized trial[J].Eur Heart J,2003,24(5):412-420.
  • 4[4]Solomon SD,Rice MM,A Jablonskik K,et al.Renal function and effectiveness of angiorensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the prevention of events with ACE inhibitor (PEACE) trail[J].Circulation,2006,114(1):26-31.
  • 5[5]The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD).Guidelines on diabetes,pre-diabetes,and cardiovascular diseases:executive summary[J].Eur Heart J,2007,28(1):88-136.
  • 6[6]Ruggenenti P,Perna A,Ganeva M,et al.Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes:a post hoc analysis of the BENEDICT trial[J].J Am Soc Nephrol,2006,17(12):3472-3481.
  • 7[7]Yano Y,Hoshide S,Ishikawa J,et al.The differential effects of angiotensin Ⅱ type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients[J].Am J Hypertens,2007,20(5):565-572.
  • 8[8]Ruilope LM,Redón J,Schmieder R.Cardiovascular risk reduction by reversing endothelial dysfunction:ARBs,ACE inhibitors,or both? Expectations from the ONTARGET Trial Programme[J].Vasc Health Risk Manag,2007,3 (1):1-9.
  • 9[9]National Kidney Foundation K/DOQI clinical practice guidelines on managing dyslipidemias in chronic kidney disease[J].Am J Kidney Dis,2003,41(Suppl 3):S1-S77.
  • 10[10]Grundy SM,Cleeman JI,Merz CN,et al.Implications of recent clinical trials for the National Cholesterol EducationProgram Adult Treatment Panel Ⅲ guidelines[J].Circulation,2004,110(2):227-239.

同被引文献31

引证文献5

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部